Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study

Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study

Abstract Background Ibrutinib is an oral irreversible inhibitor of Bruton’s tyrosine kinase, indicated for the treatment of chronic lymphocytic leukaemia. The drug is generally well tolerated; however, not infrequent side effects are reported, with the major two being bleeding and ibrutinib-related...

Full description

Bibliographic Details
Main Authors: Gianluigi Reda, Bruno Fattizzo, Ramona Cassin, Veronica Mattiello, Tatiana Tonella, Diana Giannarelli, Ferdinando Massari, Agostino Cortelezzi
Format: Article
Language:English
Published: BMC 2018-06-01
Series:Journal of Hematology & Oncology
Subjects:
Chronic lymphocytic leukaemia
Ibrutinib
Atrial fibrillation
Cardio-oncology
Online Access:http://link.springer.com/article/10.1186/s13045-018-0626-0

Internet

http://link.springer.com/article/10.1186/s13045-018-0626-0

Similar Items